Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312075 | 0.90 | ALDH1A1 (0.55) | ALDH1A1RECQLGPBAR1CYSLTR1TSHR | |
| SCHEMBL4568918 | 0.90 | KMT2A (0.57) | KMT2AALDH1A1RECQLGPBAR1CYSLTR1 | |
| 1,3-Dipropoxybenzene SCHEMBL73716 | 0.89 | KMT2A (0.63) | KMT2AGPBAR1CYSLTR1KDM4ETSHR | |
| SCHEMBL48418 | 0.89 | ALDH1A1 (0.70) | KMT2AALDH1A1RECQLTSHRNR1I2 | |
| SCHEMBL4568928 | 0.89 | KMT2A (0.60) | KMT2AALDH1A1GPBAR1CYSLTR1TSHR | |
| SCHEMBL25182698 | 0.88 | ALDH1A1 (0.57) | KMT2AALDH1A1RECQLKDM4ETSHR | |
| Ethylene Glycol SCHEMBL7206927 | 0.87 | ALDH1A1 (0.67) | KMT2AALDH1A1RECQLTSHRNR1I2 | |
| SCHEMBL4568921 | 0.87 | KMT2A (0.58) | KMT2AGPBAR1CYSLTR1TSHRNR1H4 | |
| Phenoxyethanol SCHEMBL12100847 | 0.86 | ALDH1A1 (0.79) | KMT2AALDH1A1RECQLNR1I2LTA4H | |
| SCHEMBL19978961 | 0.85 | KMT2A (0.49) | KMT2AALDH1A1RECQLKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9441306-B2 | Method for cathodic corrosion protection of chromium surfaces | ATOTECH DEUTSCHLAND GMBH (DE) | 2016-09-13 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160168725-A1 | METHOD FOR CATHODIC CORROSION PROTECTION OF CHROMIUM SURFACES | ATOTECH DEUTSCHLAND GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| CN-1105145-C | Thermoplastic resin composition | DAICEL CHEM (JP) | 2003-04-09 | — | — | CN | disclosed |
| EP-1045826-A1 | PROCESS FOR THE PREPARATION OF ISOPROPYL-METHYL- 2-(3-N-PROPOXYPHENOXY)ETHYL]AMINE | AstraZeneca AB (SE) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999032430-A1 | PROCESS FOR THE PREPARATION OF ISOPROPYL-METHYL-[2-(3-N-PROPOXYPHENOXY)ETHYL]AMINE | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | disclosed |
| CN-1206027-A | Thermoplastic resin composition | DAICEL CHEM (JP) | 1999-01-27 | — | — | CN | disclosed |
| CN-1170015-A | Thermoplastic resin composition | DAICEL CHEM (JP) | 1998-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | KMT2A 3739/4885ALDH1A1 2745/4885RECQL 1353/4885 |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ALDH1A1 140/4885RECQL 914/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | KMT2A 3986/4885ALDH1A1 2978/4885RECQL 1515/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | KMT2A 3986/4885ALDH1A1 2978/4885RECQL 1515/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | KMT2A 3739/4885ALDH1A1 2745/4885RECQL 1353/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | KMT2A 3760/4885ALDH1A1 2729/4885RECQL 1318/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ALDH1A1 140/4885RECQL 914/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ALDH1A1 140/4885RECQL 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.